Related Experiment Video
Updated: May 16, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia
Ming-Jen Lee1, Kuo-Liong Chien, Ming-Fong Chen
1Department of Neurology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Background:
This study aimed to investigate whether the body mass index (BMI) in combination with genetic variations in APOE and APOA5_'T' alleles modulates the risk of sHTG.
Methods:
There were 255 moderate HTG (TG ≥2.26 and <5.65 mmol/L) and 176 sHTG (TG ≥5.65 mmol/L) and 304 controls (TG <2.26 mmol/L) were recruited. APOE epsilon alleles were genotyped using sequence-specific primers; the APOA5_'T' allele (c.553G>T, rs2075291) was identified using a restriction site polymorphism. Overweight/obesity was defined as BMI ≥25 kg/m(2) and non-overweight as BMI <25 kg/m(2).
Results:
Multivariate logistic regression analysis showed, in addition to APOA5_'T' allele, a significant interaction between BMI ≥25 kg/m(2) and APOE4 carriers on the risk of sHTG. Subjects with diagnosis of diabetes, current smoking, hypertension, levels of non-high density lipoprotein, and BMI ≥25 kg/m(2) were significant determinants of sHTG. The odds ratio (95% confidence intervals) of overweight/obese APOE4 carriers for sHTG was 13.56 (4.89-37.59) more than those of non-overweight non-APOE4 carriers, while the odds ratio for sHTG in overweight/obese patients with the APOA5_'T' allele was 15.83 (7.77-32.26) higher than those of non-overweight non-APOA5 carriers.
Conclusions:
Overweight/obesity may potentiate the genetic variants of the APOE4 and APOA5_'T' alleles on the risk of sHTG.
Related Concept Videos
Atherosclerosis III: Management
Obesity
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
